You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股榮辱互見 聯邦及翰森製藥續升約5%-5.5% 國藥及艾美跌逾半成
亞太股市除印尼逆穩外,全面受壓,日經曾低見31,671,半日收31,786,急挫529點或1.6%;深成及韓股續吐1.1%及1.2%,報9,954及2,426,其餘跌幅均少於1%。 恆指繼上周五回吐424點或2.3%、結束六連升累漲1,042點或近6.1%後,今早低開10點報17,803,反覆受壓,高低見17,858/17,708,現報17,747,續吐65點或近0.4%;國指續吐0.5%報6,085。 醫藥板塊今天榮辱互見。藍籌翰森製藥(03692.HK)連續第九天穩步上升,今早股價升破百天線(11.6元),最高見12.08元,現報11.96元,續升5.5%。獲高盛唱好的聯邦制藥(03933.HK)四連升兼屢探頂,最高見9.18元創逾三年高,現報9.17元,續升4.9%。三葉草生物-B(02197.HK)回升4.2%報0.75元,股價重越10天線。藍籌藥明生物(02269.HK)反覆回升1.7%報49.95元。 然而,藍籌國藥(01099.HK)扭三連升,回吐5.3%報21.3元,股價失守250天線(21.9元)。艾美疫苗(06660.HK)續跌5.3%報10.38元。騰盛博藥-B(02137.HK)反覆續跌4.5%報2.56元。開拓-B(09939.HK)反覆回吐3.8%報2.79元。金斯瑞生物(01548.HK)反覆續吐2.5%報21.05元。康希諾(06185.HK)反覆續跌2%報24.9元,股價暫守50天線(24.75元)。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account